Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease -- Varenhorst et al. 30 (14): 1744 Data Supplement - Supplementary Data -- European Heart Journal

European Heart Journal ():;

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Eur Heart J Varenhorst et al. 30: 1744

Supplementary Data

Files in this Data Supplement:

Supplementary Tables - Supplementary Tables